Undervalued transition play: Tandem’s PayGo shift may temporarily suppress reported revenue while building a stickier, higher-margin recurring diabetes technology platform.
Overview
Tandem Diabetes Care is a specialized diabetes technology company focused on automated insulin delivery systems that reduce the burden of intensive insulin therapy. Its t:slim X2, Mobi, and Control-IQ platforms create a durable installed base, while proprietary cartridges and infusion sets generate recurring, high-margin revenue. The company serves Type 1 diabetes patients and an expanding insulin-intensive Type 2 population, with roughly 70% of revenue from the U.S. Its differentiation comes from ease of use, small form factors, mobile control, software upgrades, and Dexcom/Abbott CGM interoperability.